Predict your next investment

Corporate Venture
lillyasiaventures.com

See what CB Insights has to offer

Investments

195

Portfolio Exits

43

Funds

6

Partners & Customers

2

About Lilly Asia Ventures

Lilly Asia Ventures (LAV) is a biomedical venture capital firm, with offices in Shanghai, Hong Kong, and Palo Alto. Its vision is to become the trusted partner for exceptional entrepreneurs seeking smart capital and to build great companies developing breakthrough products that treat diseases and improve human health.

Lilly Asia Ventures Headquarter Location

Room 2909-14, 168 Hubin Road Huangpu District

Shanghai, Shanghai, 200021,

China

+86 21 2316 9588

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Lilly Asia Ventures

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Lilly Asia Ventures in 1 CB Insights research brief, most recently on Oct 14, 2019.

Latest Lilly Asia Ventures News

Rona Therapeutics Announces Completion of $33 Million Series A Financing to Advance Global Discovery and Development of RNA Therapeutics

Apr 7, 2022

News provided by Share this article Share this article - Funding from long-term investors to build leading delivery platform and scalable drug discovery engine to enable modular and programmable medicines - Company is harnessing the potential of RNA therapeutics to deliver medicines to liver and extrahepatic tissues with specific, stable and prolonged effects SHANGHAI, April 7, 2022 /PRNewswire/ -- Rona Therapeutics, a fully integrated platform company dedicated to the discovery, development and manufacturing of RNA therapeutics announces the successful completion of $33 million Series A financing to advance proprietary delivery platform and initial pipeline of therapeutics. The round was supported by a group of blue-chip investors including Lilly Asia Ventures, CMB International, Platanus, Fontus Capital and Lanting Capital. Founded in 2021, Rona Therapeutics aims to establish innovative and disruptive RNA medicines with proprietary platform to enable therapeutics with more specific, stable and prolonged effects. The RNA medicines from Rona Therapeutics are modular and programmable modalities targeting disease areas across metabolic diseases, neurological diseases and ophthalmology diseases via different delivery systems. The company is building state-of-the-art facilities to expand nucleic acid synthesis, delivery platform, oligonucleotide chemical modification, RNA biology and manufacturing capability to realize the potential of powerful RNA therapeutics. "We are grateful to have strong support from leading life science investment firms in this financing round. The ability to impact at RNA level will lead to transformative wave of new medicines in this era," said Stella SHI, CEO and co-founder of Rona Therapeutics. "We are looking forward to working with collaborators and financial partners, as our company vision is to turn this powerful technology into therapeutics to benefit patients." "Since launch, Rona Therapeutics has made remarkable progress in building delivery platform and advancing therapeutics into IND. The company is well positioned to become a major player in this space with scalable platform and high potential pipeline programs," said Dr. Chuan He, scientific advisor of Rona Therapeutics. "With decades-long exploratory work to decode nucleic acid therapeutics, Rona has the potential to become a leader in RNA medicines to discover and develop transformative therapeutics," said Dr. Roberto Guerciolini, scientific advisor of Rona Therapeutics. About Rona Therapeutics Rona Therapeutics is a pioneering RNA therapeutics platform company dedicated to discovery and development of modular and programmable RNA medicines to deliver to patients around the world. The company is founded by industry veteran with deep expertise in RNA therapeutics program execution and world leading scientific advisors with rigorous biology understanding in the RNA space. About Lilly Asia Ventures Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm founded in 2008, with offices in Shanghai, Hong Kong, and Palo Alto. Our vision is to become the trusted partner for exceptional entrepreneurs seeking smart capital and to build great companies developing breakthrough products that treat diseases and improve human health. About CMBI Incorporated in Hong Kong, CMB International Capital Corporation Limited ("CMBI") is an integrated financial institution providing comprehensive and professional services to institutional, corporate and individual customers both domestically and overseas. As a wholly-owned subsidiary of China Merchants Bank ("CMB"), CMBI leverages CMB's synergy and coordination in domestic and overseas markets as well as CMB's strong resources and outstanding social reputation. CMBI and its subsidiaries have been actively implementing diversified business strategies and have established main business segments including Corporate Finance, Asset Management, Wealth Management, and Equity and Structured Finance. About Fontus Capital Fontus Capital was founded in 2015, with focus on life science, specializing in pharmaceutical, biotechnology, medical device and services around the world. Our mission is to improve the lives of patients and offer innovative solutions to address the unmet medical needs. About Lanting Capital LanTing Capital (LTC) is a cross-border, pharmaceutical-focused strategic private equity firm. Founded by pharmaceutical veterans and asset management experts, LTC leverages our unparalleled industry knowledge and network plus deep financial market know-how across the USA, China and Europe to unlock unique cross-border growth opportunities for our portfolio companies and investors. LanTing is currently operating in Princeton (USA), Milan (Italy), Saanen (Switzerland), and Hangzhou (China). For more information on Rona Therapeutics, including how partnership opportunities, and job openings, visit www.ronatherapeutics.com . For Further information,

Lilly Asia Ventures Investments

195 Investments

Lilly Asia Ventures has made 195 investments. Their latest investment was in ProfoundBio as part of their Series A - II on June 6, 2022.

CBI Logo

Lilly Asia Ventures Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

6/2/2022

Series A - II

ProfoundBio

$70M

No

6

4/7/2022

Series A

Rona Therapeutics

$33M

Yes

2

4/7/2022

Series A

Darui Bio

$33M

Yes

3

3/14/2022

Series D

Subscribe to see more

Subscribe to see more

10

2/28/2022

Series A

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/2/2022

4/7/2022

4/7/2022

3/14/2022

2/28/2022

Round

Series A - II

Series A

Series A

Series D

Series A

Company

ProfoundBio

Rona Therapeutics

Darui Bio

Subscribe to see more

Subscribe to see more

Amount

$70M

$33M

$33M

$99M

New?

No

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

6

2

3

10

10

Lilly Asia Ventures Portfolio Exits

43 Portfolio Exits

Lilly Asia Ventures has 43 portfolio exits. Their latest portfolio exit was Veritas Genetics on March 29, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

3/29/2022

Acquired

$99M

3

1/7/2022

IPO

$99M

Public

4

12/10/2021

IPO

$99M

Public

1

11/5/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

10/19/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

3/29/2022

1/7/2022

12/10/2021

11/5/2021

10/19/2021

Exit

Acquired

IPO

IPO

IPO

IPO

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Public

Subscribe to see more

Subscribe to see more

Sources

3

4

1

10

10

Lilly Asia Ventures Fund History

6 Fund Histories

Lilly Asia Ventures has 6 funds, including LAV Biosciences Fund V.

Closing Date

Fund

Fund Type

Status

Amount

Sources

2/19/2019

LAV Biosciences Fund V

Multi-Stage Venture Capital

Closed

$750M

1

8/14/2017

LAV Biosciences Fund IV

Subscribe to see more

Subscribe to see more

$99M

10

12/31/2016

LAV Biosciences Fund III

Subscribe to see more

Subscribe to see more

10

12/31/2007

Lilly Asia Ventures I

Subscribe to see more

Subscribe to see more

$99M

10

Lilly Asia Ventures Fund III

10

Closing Date

2/19/2019

8/14/2017

12/31/2016

12/31/2007

Fund

LAV Biosciences Fund V

LAV Biosciences Fund IV

LAV Biosciences Fund III

Lilly Asia Ventures I

Lilly Asia Ventures Fund III

Fund Type

Multi-Stage Venture Capital

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Closed

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$750M

$99M

$99M

Sources

1

10

10

10

10

Lilly Asia Ventures Partners & Customers

2 Partners and customers

Lilly Asia Ventures has 2 strategic partners and customers. Lilly Asia Ventures recently partnered with Kumquat Biosciences on July 7, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

7/29/2021

Partner

United States

Lilly and Kumquat Biosciences Announce Collaboration to Discover and Develop Novel Small Molecules that Stimulate Tumor-Specific Immune Responses.

`` Kumquat Biosciences is developing a novel small molecule IO platform and this collaboration with Lilly Asia Ventures is expected to greatly expedite the development of this platform and maximize its full potential .

1

11/6/2018

Partner

United States

Subscribe to see more

Subscribe to see more

10

Date

7/29/2021

11/6/2018

Type

Partner

Partner

Business Partner

Country

United States

United States

News Snippet

Lilly and Kumquat Biosciences Announce Collaboration to Discover and Develop Novel Small Molecules that Stimulate Tumor-Specific Immune Responses.

`` Kumquat Biosciences is developing a novel small molecule IO platform and this collaboration with Lilly Asia Ventures is expected to greatly expedite the development of this platform and maximize its full potential .

Subscribe to see more

Subscribe to see more

Sources

1

10

Lilly Asia Ventures Team

3 Team Members

Lilly Asia Ventures has 3 team members, including current Managing Partner, Fei Chen.

Name

Work History

Title

Status

Fei Chen

Managing Partner

Current

Yi Shi

Managing Partner

Current

Hongbo Lu

Managing Partner

Former

Name

Fei Chen

Yi Shi

Hongbo Lu

Work History

Title

Managing Partner

Managing Partner

Managing Partner

Status

Current

Current

Former

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.